1. Home
  2. LTBR vs CGEM Comparison

LTBR vs CGEM Comparison

Compare LTBR & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lightbridge Corporation

LTBR

Lightbridge Corporation

HOLD

Current Price

$13.01

Market Cap

578.2M

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$9.97

Market Cap

671.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LTBR
CGEM
Founded
1992
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
578.2M
671.7M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LTBR
CGEM
Price
$13.01
$9.97
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$28.00
AVG Volume (30 Days)
1.1M
1.2M
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.51
$5.68
52 Week High
$31.34
$13.33

Technical Indicators

Market Signals
Indicator
LTBR
CGEM
Relative Strength Index (RSI) 35.88 47.81
Support Level $12.95 $9.48
Resistance Level $15.19 $10.42
Average True Range (ATR) 1.04 0.72
MACD -0.01 -0.20
Stochastic Oscillator 3.02 14.09

Price Performance

Historical Comparison
LTBR
CGEM

About LTBR Lightbridge Corporation

Lightbridge Corp is a United States-based nuclear fuel technology company. The business activity of the firm is functioned through one business segment, which is the development and commercialization of its nuclear fuel. The Nuclear Fuel Technology segment develops next generation nuclear fuel technology that increases the power output of commercial reactors and reduces the cost of generating electricity. Geographically, its operations are functioned through the region of Unites States.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: